NCT05885919View on ClinicalTrials.gov

Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke

PHASE3UnknownINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Ischemic Stroke, AcuteTreatment Outcome
Interventions
DRUG

Edaravone Dexborneol Concentrated Solution for injection

Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.

DRUG

Edaravone Dexborneol placebo

Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.

Trial Locations (3)

410008

Brain Hospital of Hunan Province, Changsha

Hunan Provincial People's Hospital, Changsha

XiangYa School of Medicine, Changsha

Sponsors
All Listed Sponsors
collaborator

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

lead

Xiangya Hospital of Central South University

OTHER